Characterized by a rapidly increasing prevalence, elevated mortality and rehospitalization
rates, and inadequacy of pharmaceutical therapies, heart failure with preserved ejection …

The field of durable mechanical circulatory support (MCS) has undergone an incredible
evolution over the past few decades, resulting in significant improvements in longevity and …

Aortic stenosis (AS) affects about 1.5 million people in the United States and is associated
with a 5-year survival rate of 20% if untreated. In these patients, aortic valve replacement is …

Heart failure with preserved ejection fraction (HFpEF) is a major challenge in cardiovascular
medicine, accounting for≈ 50% of all cases of heart failure. Despite the ongoing efforts, no …

Heart failure with preserved ejection fraction (HFpEF) is a syndrome with an unfavorable
prognosis, and the number of the patients continues to grow. Because there is no effective …

Heart failure with preserved ejection fraction (HFpEF) is increasing in prevalence and
represents approximately 50% of all heart failure (HF) patients. Patients with this complex …

A novel pump, the left atrial assist device (LAAD), is a device specifically for the treatment of
heart failure with preserved ejection fraction (HFpEF). The LAAD is a mixed-flow pump that …

Successful therapy of heart failure with preserved ejection fraction (HFpEF) remains a major
unmet clinical need. Device-based treatment approaches include the interatrial shunt device …

Heart failure with preserved ejection fraction (HFpEF) is characterized by diastolic
dysfunction and multiple comorbidities. The number of patients is continuously increasing …

Increased cardiac stiffness hinders proper left ventricular (LV) expansion, resulting in
decreased volume and diastolic dysfunction. LV expanders are spring-like devices designed …